- Pear Therapeutics launches Somryst as the first PDT intended for use in the treatment of patients with chronic insomnia aged > 22yrs. It addresses the issues of chronic insomnia by delivering (CBTi) approach that trains the brain and body to sleep
- In a study of ~1,400 adults with CI, PDT reduced the amount of time it took to fall asleep (45%), reduced the amount of time spent awake at night (52%) and reduced severity of insomnia symptoms (45%) with continued improvement at 6 & 12 mos. post-treatment
- Somryst will be promoted via a fully virtual experience, combining telemedicine visits and PDT prescribing and dispensation via PearConnect
Click here to read full press release/ article | Ref: Pear therapeutics | Image: MobileHealthNews
The post Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience first appeared on PharmaShots.